Noile-Immune Biotech Inc.

Tokyo Stock Exchange 4893.T

Noile-Immune Biotech Inc. Price to Sales Ratio (P/S) on January 14, 2025: 22.70

Noile-Immune Biotech Inc. Price to Sales Ratio (P/S) is 22.70 on January 14, 2025, a -22.52% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Noile-Immune Biotech Inc. 52-week high Price to Sales Ratio (P/S) is 29.79 on July 30, 2024, which is 31.25% above the current Price to Sales Ratio (P/S).
  • Noile-Immune Biotech Inc. 52-week low Price to Sales Ratio (P/S) is 18.85 on August 05, 2024, which is -16.93% below the current Price to Sales Ratio (P/S).
  • Noile-Immune Biotech Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 23.20.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Tokyo Stock Exchange: 4893.T

Noile-Immune Biotech Inc.

CEO Mr. Koji Tamada M.D., Ph.D.
IPO Date June 28, 2023
Location Japan
Headquarters 2-12-10
Employees 28
Sector Health Care
Industries
Biotechnology
Description

Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email